 Okay, I'm Gennady Bratslavsky. I'm a chair of the Department of Urology here at SUNY Syracuse, a state university of New York. I'm here with Dr. Mati Malapur, who is the lead and the director of the kidney cancer translational program here at SUNY Upstate. It was Dr. Malapur's original idea because of much of his expertise in the basic science and translational research in hereditary kidney disorder known as BHD, Burkhag De Bay. It is something that is very poorly known among community and many patients and many patients are not diagnosed until later when they actually experience some of the symptoms and often end up having self-diagnosis. So, Dr. Malapur's idea was to combine this as both clinical as well as a translational research. My name is Mati Malapur. I'm an assistant professor at the Department of Urology here at Upstate Medical University. I'm also the director of the kidney cancer biology section here at Upstate. The topic of this session title of our paper is the Sixth BHD Symposium and First International Upstate Kidney Cancer Symposium, Latest Scientific and Clinical Discoveries. It really summarizes the outcome of the meeting that we organized and we posted last year here at Upstate. What's so interesting about this meeting and we have summarized it in our paper is that we brought in clinicians, basic researchers, and also patients that are suffering from this particular type of kidney cancer called BHD, as well as other types of kidney cancer under one roof and we had a positive interaction in terms of what's the latest discoveries, what are the latest treatments for these patients, and also for the patients that had an opportunity to discuss the problems and what is actually available for them in terms of latest therapeutic strategies. We were very excited to host this meeting here. Last one was previously held at Paris and we had the bar set quite high. The beauty of this meeting was the fact that while we already have many patients coming from most of the United States as well as from the overseas for some of their kidney cancer treatment and many other urologic malignancy treatments, we are now part of the more comprehensive structure which is known as BHL Comprehensive Clinical Center and we treat so many different hereditary kidney type of cancers, those that are found in families and this was truly an opportunity for us to share our expertise. Both Dr. Malapur and myself, we came from the National Cancer Institute, National Institutes of Health where we both spent a few years each and we had the pleasure of working back there together and really learned quite a bit about this very rare type of kidney hereditary cancers and we are now very happy to be able to provide patients as well as clinicians with guidance on how to manage these patients as well as help other basic science researchers with their focus as well as contributing to the literature by doing symposium like that. This is a benefit for all type of a kidney.